Literature DB >> 22324758

Rapid identification of low level glycation sites in recombinant antibodies by isotopic labeling with 13C6-reducing sugars.

Jennifer Zhang1, Taylor Zhang, Lihua Jiang, Daniel Hewitt, Yungfu Huang, Yung-Hsiang Kao, Viswanatham Katta.   

Abstract

Recombinant antibodies exhibit low levels of glycation from exposure to reducing sugars during production. As the glycation sites are typically distributed across the entire antibody, the levels at any one site are low and it becomes difficult to detect them in the conventional peptide maps. A model antibody was subjected to forced glycation by incubating with a high concentration of a 1:1 mixture of (12)C(6)/(13)C(6) reducing sugars with the assumption that the same sites in the native antibody will be glycated but to a lower extent. This approach simplified the detection of glycated tryptic peptide elution in the LC/MS analysis by giving a unique signature of two molecular ions with equal intensity and differing by 6.018 Da. An in-house developed script automatically processed large data files to generate a list of such peptide mass pairs. The high mass accuracy of the Orbitrap allowed us to assign the sequences unambiguously by comparison with all possible glycated peptide masses. This sequence list was subsequently used to verify their presence/absence in the digest of the native antibody. This work flow enabled rapid and confident identification of site-specific glycation even when levels are below 0.5%. We found the glycation sites to be distributed across the entire antibody studied.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22324758     DOI: 10.1021/ac202995x

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  7 in total

1.  A chemical and computational approach to comprehensive glycation characterization on antibodies.

Authors:  Ramsey A Saleem; Brittany R Affholter; Sihong Deng; Phil C Campbell; Kelli Matthies; Catherine M Eakin; Alison Wallace
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 2.  Glycation of antibodies: Modification, methods and potential effects on biological functions.

Authors:  Bingchuan Wei; Kelsey Berning; Cynthia Quan; Yonghua Taylor Zhang
Journal:  MAbs       Date:  2017-03-08       Impact factor: 5.857

Review 3.  In vitro and in vivo modifications of recombinant and human IgG antibodies.

Authors:  Hongcheng Liu; Gomathinayagam Ponniah; Hui-Min Zhang; Christine Nowak; Alyssa Neill; Nidia Gonzalez-Lopez; Rekha Patel; Guilong Cheng; Adriana Z Kita; Bruce Andrien
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

4.  Comparison of modification sites in glycated crystallin in vitro and in vivo.

Authors:  Martyna Kielmas; Monika Kijewska; Alicja Kluczyk; Jolanta Oficjalska; Bożena Gołębiewska; Piotr Stefanowicz; Zbigniew Szewczuk
Journal:  Anal Bioanal Chem       Date:  2015-01-31       Impact factor: 4.142

5.  Reg-2, A Downstream Signaling Protein in the Ciliary Neurotrophic Factor Survival Pathway, Alleviates Experimental Autoimmune Encephalomyelitis.

Authors:  Hong Jiang; Ke-Wei Tian; Fan Zhang; Beibei Wang; Shu Han
Journal:  Front Neuroanat       Date:  2016-05-09       Impact factor: 3.856

6.  The NISTmAb tryptic peptide spectral library for monoclonal antibody characterization.

Authors:  Qian Dong; Yuxue Liang; Xinjian Yan; Sanford P Markey; Yuri A Mirokhin; Dmitrii V Tchekhovskoi; Tallat H Bukhari; Stephen E Stein
Journal:  MAbs       Date:  2018-03-06       Impact factor: 5.857

7.  Monitoring glycation levels of a bispecific monoclonal antibody at subunit level by ultrahigh-resolution MALDI FT-ICR mass spectrometry.

Authors:  Christoph Gstöttner; Dietmar Reusch; Markus Haberger; Irina Dragan; Peter Van Veelen; David P A Kilgour; Yury O Tsybin; Yuri E M van der Burgt; Manfred Wuhrer; Simone Nicolardi
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.